Introduction {#S0001}
============

Nasopharyngeal carcinoma (NPC) is a malignant head and neck cancer with an unbalanced global distribution. The peak incidence in endemic regions including southern China and Southeast Asia reaches 50 cases per 100,000.[@CIT0001] Radiotherapy is the mainstay treatment for NPC. Despite the extraordinary local control rates brought by radiotherapy, this treatment may cause both acute and chronic adverse effects to the soft tissues and bones surrounding the nasopharynx. As more irradiated NPC patients survive after treatment, the presence of various post-radiation complications should raise more concerns.[@CIT0002]

Post-radiation nasopharyngeal necrosis (PRNN) is a devastating adverse effect of radiotherapy for NPC.[@CIT0003] Patients with PRNN usually present with severe headache, foul odor, and epistaxis, which seriously compromise patients' quality of life.[@CIT0003],[@CIT0004] Severe and even fatal consequences of PRNN, including massive hemorrhage, intracranial infection, and cachexia, have occasionally been seen,[@CIT0003],[@CIT0004] especially when the carotid sheath is involved and the carotid artery is eroded.[@CIT0003] Published literature for PRNN is quite limited, and the survival outcomes of these patients are generally poor, with Yang et al[@CIT0005] reporting 1-year and 2-year overall survival (OS) rates of 65.0% and 51.6%, respectively.[@CIT0005] Therefore, it is essential to facilitate early identification of NPC patients with a higher tendency for PRNN and implement effective interventions to prevent the occurrence of as well as reverse the deterioration of PRNN.

In recent years, with an improved understanding of PRNN, emerging studies focused on finding the risk factors leading to PRNN.[@CIT0003],[@CIT0004],[@CIT0006]--[@CIT0009] The accumulated dosage of radiation is generally recognized as an important risk factor for the severity of necrosis.[@CIT0003],[@CIT0004],[@CIT0006]--[@CIT0008] Yu et al's study[@CIT0009] established a model that includes sex, pretreatment necrosis, accumulated total prescription dose to GTV, and recurrent tumor volume to predict the risk of nasopharyngeal necrosis (NPN) in NPC patients who receive re-irradiation.[@CIT0009] In addition to their findings, we also found a strong correlation between the development of PRNN and some inflammatory and nutritional factors in our clinical practice. To better understand the predictive potential of these factors and make a thorough analysis of the pathophysiology of PRNN, a nomogram is developed to estimate the individual risk of PRNN. The nomogram is a reliable statistical predictive model, which is simple and explicit, and can accurately present the risk of PRNN. We hope this nomogram could serve as a valuable decision-making tool for clinicians to take precautions against PRNN.

Methods {#S0002}
=======

Patients {#S0002-S2001}
--------

From January 2007 to December 2012, we retrospectively reviewed the clinical data of 7144 stage I--IVb NPC patients treated consecutively at Sun Yat-sen University Cancer Center (SYSUCC). The inclusive criteria of this study were as follows: 1) histopathologically confirmed NPC; 2) age ≥18 years; 3) received radical radiotherapy treatment; 4) radiologically measurable disease; 5) Karnofsky performance score \>60; 6) absence of pregnancy, lactation, and other malignant disease; and 7) normal renal and liver function. All patients were evaluated by complete physical examination, head and neck computed tomography (CT) or magnetic resonance imaging (MRI), chest radiograph, abdominal sonography, electrocardiography, nasopharyngoscopy, bone scan or positron emission tomography--computed tomography (PET--CT), and laboratory tests including blood routine and biochemical profiles. Patient information such as sex, age, family history of NPC, smoking status, and history of cardiovascular disease and diabetes mellitus was also collected besides the pretreatment evaluations. All patients were staged based on the seventh TNM staging manual from the American Joint Committee on Cancer.[@CIT0010] This research was conducted in accordance with the Declaration of Helsinki. The Clinical Research Ethics Committee of the SYSUCC approved this study and each participant provided written informed consent prior to treatment.

Diagnosis and treatment of PRNN {#S0002-S2002}
-------------------------------

The diagnosis of PRNN was made according to the symptoms of and results from nasopharyngoscopy or MRI. Symptoms like a foul nasal smell, refractory headache, and thick necrotic secretions were strong indicators of PRNN. Nasopharyngoscopy revealed necrotic lesions and sometimes exposed bone covered by secretions in the nasopharyngeal cavity. MRI images often showed a discontinuous nasopharyngeal mucosa line and/or nonenhanced tissue defects. After PRNN was detected, endoscopic debridement and excision every 2 weeks and daily nasopharyngeal irrigation with 2% aquae hydrogen dioxide or saline were given. Endoscopic necrectomy was performed when no contraindications were observed. Systemic antibiotics and intravenous nutrition support were provided if necessary.

Follow-up and outcomes {#S0002-S2003}
----------------------

OS was defined from the first day of diagnosis of NPC to the day of death from any reasons. In the first 3 years, all patients received reexamination every 3 months, and then every 6 months until death. A complete physical examination was performed at each visit. Besides, nasopharyngoscopy, contrast-enhanced MRI of the nasopharynx and neck, ultrasound/enhanced CT scan of the abdomen, and radiography/enhanced CT scan of the chest were done routinely. PET--CT was considered if necessary.

Statistical analysis {#S0002-S2004}
--------------------

Categorical variables were classified based on clinical findings, and continuous variables were transformed into categorical variables based on routine cutoff points in clinical application. The standard chi-square test was used for comparative analysis. The associations between NPC patients' clinical characteristics and the risk of PRNN were evaluated using univariate logistic regression analysis. Significant variables with *p*\<0.05 were entered into the multivariate logistic analysis to identify the independent risk factors for PRNN. On the basis of results from the multivariable analysis, a nomogram for PRNN probability was constructed using a backward step-down process, and model fitting was evaluated using the Akaike information criterion. The Hosmer--Lemeshow test was used to assess the fit of the regression model. The discriminative performance of the nomogram was assessed by receiver operating characteristic (ROC) curve, and the calibration was assessed by the calibration curve.

The survival curve was estimated using the Kaplan--Meier method, and comparisons of the survival rate between or among patients with different characteristics were assessed by the log-rank test.[@CIT0011] All statistical analyses were carried out with SPSS version 21.0 (IBM Corporation, Armonk, NY, USA) or with R 3.5.1 (The R Foundation for Statistical Computing, Vienna, Austria). For all analyses, a result of *p*\<0.05 was considered statistically significant.

Results {#S0003}
=======

Clinical characteristics and failure patterns {#S0003-S2001}
---------------------------------------------

From January 2007 to December 2012, data on a consecutive series of 7144 NPC patients (5279 male and 1865 female) treated at SYSUCC were analyzed. The median age was 46 years (IQR, 39--55 years). After the median interval of 12.4 months from the end of treatment to the detection of NPN, a total of 206 patients had developed NPN, yielding an incidence rate of 2.9%. Details of the cohort are shown in [Table 1](#T0001){ref-type="table"}.Table 1Patient characteristics of the cohortCharacteristicNumber of patients (%)Total cohort (n=7144)Control cohort (n=6938)Necrotic cohort (n=206)*p***Age (years)**0.009 18--453566 (49.9)3482 (50.2)84 (40.8) ≥463578 (50.1)3456 (49.8)122 (59.2)**Gender**0.091 Female1865 (26.1)1822 26.3)43 (20.9) Male5279 (73.9)5116 (73.7)163 (79.1)**BMI**0.626 \<18.5603 (8.4)587 (8.5)16 (7.8) 18.5--22.93208 (44.9)3110 (44.8)98 (47.6) 23.0--27.92922 (40.9)2838 (40.9)84 (40.8) ≥28411 (5.8)403 (5.8)8 (3.9)**EBV DNA level**0.108 \<10002834 (39.7)2756 (39.7)78 (37.9) 1000--99991871 (26.2)1815 (26.2)56 (27.2) 10,000--99,9991466 (20.5)1413 (20.4)53 (25.7) ≥100,000973 (13.6)954 (13.8)19 (9.2)**Pathology type**0.001 WHO III6855 (96.0)6668 (96.1)187 (90.8) WHO I--II289 (4.0)270 (3.9)19 (9.2)**Diabetes**0.002 No6960 (97.4)6767 (97.5)193 (93.7) Yes184 (2.6)171 (2.5)13 (6.3)**Smoking history**0.246 No4359 (61.0)4225 (60.9)134 (65.0) Yes2785 (39.0)2713 (39.1)72 (35.0)**NPC family history**0.095 No6330 (88.6)6155 (88.7)175 (85.0) Yes814 (11.4)783 (11.3)31 (15.0)**T stage**0.003 T1--22119 (29.7)2077 (29.9)42 (20.4) T3--45025 (70.3)4861 (70.1)164 (79.6)**N stage**0.019 N0--13915 (54.8)3819 (55.0)96 (46.6) N2--33229 (45.2)3119 (45.0)110 (53.4)**Treatment method**0.252 RT alone1274 (17.8)1236 (17.8)38 (18.4) CCRT2568 (35.9)2493 (35.9)75 (36.4) IC+CCRT1791 (25.1)1731 (24.2)60 (25.1) Others1511 (21.1)1478 (21.3)33 (21.2)**Radiotherapy method method**0.015 IMRT4012 (56.2)3879 (55.9)133 (64.6) 2DRT3132 (43.8)3059 (44.1)73 (35.4)**Re-radiotherapy**\<0.001 No6898 (96.6)6749 (97.3)149 (72.3) Yes246 (3.4)189 (2.7)57 (27.7)**Radiotherapy dose (Gy)**0.474 ≤705763 (80.7)5601 (80.7)162 (78.6) \>701381 (19.3)1337 (19.3)44 (21.4)**LDH (U/L)**0.482 \<2456661 (93.2)6466 (93.2)195 (94.7) ≥245483 (6.8)472 (6.8)11 (5.3)**CRP (mg/L)**\<0.001 \<12745 (38.4)2696 (38.9)49 (23.8) 1--32276 (31.9)2203 (31.8)73 (35.4) ≥32123 (29.7)2039 (29.4)84 (40.8)**HGB (g/L)**\<0.001 \<110173 (2.4)155 (2.2)18 (8.7) 110--1504561 (63.8)4411 (63.6)150 (72.8) ≥1502410 (33.7)2372 (34.2)38 (18.4)**ALB (g/L)**\<0.001 \<3526 (0.4)20 (0.3)6 (2.9) ≥357118 (99.6)6918 (99.7)200 (97.1)[^2]

Among the NPN population, 57 (27.7%) developed the condition after receiving re-irradiation. The median follow-up was 56.8 months. The estimated 5-year OS rate for NPN patients was 63.8%, which was much lower when compared with the control cohort (63.8%, 95% CI 56.5--71.0% vs 85.6%, 95% CI 84.6--86.6%, *p*\<0.001) ([Figure 1](#F0001){ref-type="fig"}). Overall, 115 (55.6%) NPN patients died: 61 (53.0%) deaths were caused by radiation or necrosis-related adverse events including hemorrhage and intracranial infection, etc., 22 (19.1%) cases were locoregional relapse-related, while 23 (20.0%) were due to distant metastasis.Figure 1Kaplan--Meier curves for overall survival in the control cohort and the NPN cohort.**Abbreviation:** NPN, nasopharyngeal necrosis.

Factors associated with NPN {#S0003-S2002}
---------------------------

All potential influencing factors associated with NPN from clinical characteristics to laboratory indexes were analyzed in our study. The results of the univariable and multivariable analysis are summarized in [Table 2](#T0002){ref-type="table"}. Among demographic and clinical factors, older age (\>45 years) (*p*=0.008), existing status of diabetes (*p*=0.001), and pathological type of WHO I--II NPC (*p*\<0.001) were found to correlate with a higher incidence of NPN. The more advanced initial stage of both primary tumor (*p*=0.003) and nodal status (*p*=0.020) were also factors that had an impact on NPN. In terms of radiotherapy, patients receiving intensity-modulated radiotherapy or re-irradiation were more likely to develop NPN. Pretreatment laboratory results, which reflected the baseline nutritional and inflammatory status, were also collected and analyzed. Inferior levels of hemoglobin (HGB), albumin (ALB), and C-reactive protein (CRP) were all strong prognosticators for the occurrence of NPN. All significant factors in the univariable analysis were considered to enter into the multivariable analysis.Table 2Univariable analysis and multivariable analysis in the cohortCharacteristicUnivariable analyses*p*Multivariable analyses*p*HR (95% CI)HR (95% CI)**Age (years)** 18--46ReferenceReference ≥461.46 (1.10--1.94)0.0081.38 (1.02--1.87)0.035**Gender** FemaleReference Male1.35(0.96--1.90)0.084**BMI** \<18.5Reference 18.5--22.991.16 (0.68--1.98)0.596 23--281.09 (0.63--1.87)0.766 ≥280.73 (0.31--1.72)0.469**EBV DNA level** \<1000Reference 1000--99991.09 (0.77--1.55)0.627 10,000--99,9991.33 (0.93--1.89)0.120 ≥100,0000.70 (0.42--1.17)0.174**Pathology type** WHO IIIReferenceReference WHO I--II2.51 (1.54--4.09)\<0.0012.21 (1.30--3.76)0.003**Diabetes** NoReferenceReference Yes2.67 (1.49--4.77)0.0012.39 (1.28--4.45)0.006**Smoking history** NoReference Yes0.84 (0.63--1.12)0.229**NPC family history** NoReference Yes1.39 (0.94--2.06)0.095**T stage** T1--2ReferenceReference T3--41.67 (1.18--2.35)0.0031.46 (1.02--2.09)0.040**N stage** N0--1ReferenceReference N2--31.39 (1.05--1.84)0.0201.21 (0.90--1.63)0.207**Treatment method** RT aloneReference CCRT0.98 (0.66--1.45)0.914 IC+CCRT1.13 (0.75--1.70)0.569 Others0.73 (0.45--1.17)0.184**Radiotherapy method** IMRTReferenceReference 2DRT0.70 (0.52--0.93)0.0140.54 (0.39--0.74)\<0.001**Re-radiotherapy** NoReferenceReference Yes13.60 (9.75--19.15)\<0.00115.56 (10.84--22.35)\<0.001**Radiotherapy dose (Gy)** ≤70Reference \>701.14 (0.81--1.60)0.455**LDH (U/L)** \<245Reference ≥2450.77 (0.42--1.43)0.411**CRP (mg/L)** \<1ReferenceReference 1--31.82 (1.26--2.63)0.0011.87 (1.27--2.75)0.001 ≥32.27 (1.59--3.24)\<0.0011.99 (1.36--2.91)\<0.001**HGB (g/L)** \<110ReferenceReference 110--1500.29 (0.18--0.49)\<0.0010.29 (0.16--0.52)\<0.001 ≥1500.14 (0.08--0.25)\<0.0010.14 (0.07--0.26)\<0.001**ALB (g/L)** \<35ReferenceReference ≥350.10 (0.04--0.24)\<0.0010.26 (0.09--0.78)0.016[^3]

The establishment of the nomogram model for NPN prediction {#S0003-S2003}
----------------------------------------------------------

The final nomogram model was established after the model fitting procedure using the Akaike information criterion ([Figure 2](#F0002){ref-type="fig"}). It showed that re-irradiation was the dominant factor for the nomogram model, followed by HGB level \<110 g/L, ALB level \<35 g/L, and a status of diabetes. Other factors showed moderate impacts on the NPN prediction. The different status of each factor corresponds to a specific score on the point scale, and a total score could be calculated for individuals with all factors considered. By locating it on the total point scale, it is easy to predict the estimated probability of NPN incidence.Figure 2Nomogram including age, pathological type, diabetes, T stage, RT technique, re-radiotherapy, CRP levels, HGB levels, and ALB levels for the development of NPN in patients with nasopharyngeal carcinoma. The nomogram allows clinicians to obtain the probability of developing NPN corresponding to a patient's combination of covariates.**Abbreviations:** NPN, nasopharyngeal necrosis; IMRT, intensity-modulated radiotherapy; RT, radiotherapy; CRP, C-reactive protein; HGB, hemoglobin; ALB, albumin.

The discrimination and calibration ability of the nomogram {#S0003-S2004}
----------------------------------------------------------

The ROC curve was used to evaluate the discrimination of this model according to the predictive value in the logistic analysis ([Figure 3](#F0003){ref-type="fig"}). The nomogram demonstrated good discrimination ability for predicting NPN with an area under the ROC curve of 0.78 (95% CI, 0.75--0.82). The model was well calibrated according to the Hosmer--Lemeshow test (*p*=0.63). In [Figure 4](#F0004){ref-type="fig"}, the *y*-axis denotes the observed NPN probability while the *x*-axis presents the predicted probability derived from the nomogram. The calibration plot also showed satisfactory agreement between the values of prediction and observation in the cohort.Figure 3The sensitivity and specificity for the prediction of post-radiation nasopharyngeal necrosis using the nomogram model.**Abbreviation:** AUROC, area under the receiver operating characteristic curve.Figure 4Model calibration curve shows the predicted and actual probability of developing post-radiation nasopharyngeal necrosis.

Discussion {#S0004}
==========

NPN is a severe and devastating adverse event associated with radiotherapy of NPC.[@CIT0003]--[@CIT0005] NPN occurs unexpectedly and occultly deep in the nasopharynx cavity, but gradually develops as foul odor and severe headache, and sometimes leads to intracranial infection and lethal hemorrhage in severe cases.[@CIT0003],[@CIT0004][@CIT0004] Because of the rarity of this event, information about the incidence and treatment of NPN is quite limited. This was the first large-scale cohort study that provided a detailed profile of NPN patients and established a nomogram to predict the occurrence of NPN based on the clinical and laboratory indicators of NPC patients. The nomogram demonstrated good discriminative capacity and satisfactory agreement between the predicted and actual results, which should offer valuable clues for clinicians to distinguish the high-risk NPN population and maintain close surveillance for early detection.

Early NPN often appears as mucosal ulceration or a discontinuous mucosa line in MRI, but as the ulceration gradually evolves it erodes the surface of the carotid artery with numerous pathogens reproduced, which would lead to fatal osteoradionecrosis and carotid artery exposure. The NPN-related death rate was 53.0% in our report, and ranged from 40.2% to 60.3% in other studies.[@CIT0003],[@CIT0005],[@CIT0009] Worse, the death rates in patients experiencing osteoradionecrosis and carotid artery exposure were as high as 65.8% and 72.7%.[@CIT0003] In Yang et al's study,[@CIT0005] re-irradiation and carotid artery exposure were strongly and independently associated with the OS for NPN patients. Re-irradiation, which represented receiving a much higher accumulated radiation dose, could lead to hypoxia, hypovascularity, and hypocellularity in recurrent NPC patients. As a result, the normal tissue of the nasopharynx was injured and oxygen demand was increasing, which was considered a major risk factor for the development of necrosis.[@CIT0012] According to previous studies, the high rate of NPN following re-irradiation has been described with an incidence from 19.9% to 40.6%,[@CIT0013]--[@CIT0016] and accounted for 18.2--35.9% of deaths in the locally recurrent population,[@CIT0013],[@CIT0015],[@CIT0016] which far exceeded the deaths caused by tumor progression. Similar to these results, the experience of re-irradiation contributed most to the occurrence of NPN in our nomogram model. In Liu et al's report,[@CIT0016] recurrent patients who received re-irradiation exhibited comparable OS rates with those under only chemotherapy (27.5% vs 23.4%), and radiation toxicity was the only significant factor correlated with poorer OS. To balance the pros and cons as well as reduce the risk of NPN and NPN-related deaths, a cautious decision should be made to select the proper candidates for re-irradiation.

HGB was an important indicator for patients' nutritional and performance status, the level of which reflected the reduction of blood oxygen and the state of hypoxia in tumor tissues. Previous studies demonstrated that a low level of HGB was closely related to the decreased ability of the blood to carry oxygen.[@CIT0017] Additionally, the association between anemia and poor tumor oxygenation has been verified in head and neck cancers.[@CIT0018] In terms of survival conditions, multiple studies have revealed that the levels of HGB decrease were independently correlated with poorer survival outcomes in NPC patients.[@CIT0019]--[@CIT0022] Hypoxia not only reduced tumor radiosensitivity but also delayed the healing of nasopharynx mucosa and created the condition for anaerobics proliferation.[@CIT0023] In this study, we found that the pretreatment HGB concentration was also associated with the incidence of tissue necrosis. Thus, anemia may be another reason for the poor prognosis of NPN. However, whether correction of the HGB level could change this situation was still uncertain. The intervention of hyperbaric oxygen was empirically introduced to patients once NPN was detected. In our unpublished data, 75 patients received at least 2 cycles of hyperbaric oxygen; 69 patients (92%) improved to mild degrees, but the true efficacy of hyperbaric oxygen was vague and warrants further study.

ALB is the most frequently measured index to value the nutritional status as well as reflect an inflammatory condition in cancer patients. CRP is an acute-phase protein serving as a biomarker of inflammation, and has been associated with radiotherapy-induced mucositis in head and neck cancer and breast cancer.[@CIT0024],[@CIT0025] Necrosis is the outcome of a highly proinflammatory status. Meanwhile, certain molecules which are thought to promote inflammation could be also released from necrotic cells.[@CIT0026] Therefore, a vicious circle is formed. The link between CRP, ALB levels, and the prognosis of cancer was also observed by many reports.[@CIT0027]--[@CIT0030] Despite whether the tumor or tissue is the source of pretreatment CRP being unclear, the preexisting inflammatory state served as a hallmark in many solid malignancies for tumor development and impaired general condition.

As mentioned above, the development of NPN was a multistep process initiated from irradiation-caused damage to the nasopharynx mucosa, leading to an increase in oxygen demand. Hypovascularity and the low level of HGB aggravated tumor ischemia, and inflammatory cells and cytokines accumulated and interacted resulting in persistent perilesional edema. Once the necrotic lesion formed, treatment strategies including the use of antibiotics, hyperbaric oxygen, nasopharyngeal irrigation, and systemic nutritional support were just feeble attempts. Radical endoscopic necrectomy with nasal flap reconstruction ENNF was recommended by Yang et al's report,[@CIT0005] in which 44 endoscopic necrectomy with nasal flap reconstructions were performed and 36 succeeded. However, emphasis should be primarily placed on preventing NPN from happening. Our nomogram model was thus established with pretreatment indexes involved, in a wish to help clinicians to predict the possibility of NPN for each individual. High-risk patients should be closely monitored during and after treatment, and active interventions should be provided including rectifying anemia, tight glucose control, nutritional support, etc.

This study has several limitations. NPN was a small-probability event, so it was difficult to give detailed information and analyze the treatment effect of these patients given the long time span. The changes of HGB, ALB, and CRP levels during treatment were not considered in this nomogram to avoid being more complicated. External validation of this nomogram model is necessary.
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